Aminopurvalanol A

Research use only, not for human use.

Aminopurvalanol A is a competitive, selective and cell-permeable inhibitor of cyclin-dependent kinase (CDK) that potently inhibits Cyclin A/cdk2, Cyclin B/cdk1, Cyclin E/cdk2, and P35/cdk5 with IC50 of 33 nM, 33 nM, 28 nM and 20 nM, respectively.

Aminopurvalanol A is a competitive, selective and cell-permeable inhibitor of cyclin-dependent kinase (CDK) that potently inhibits Cyclin A/cdk2, Cyclin B/cdk1, Cyclin E/cdk2, and P35/cdk5 with IC50 of 33 nM, 33 nM, 28 nM and 20 nM, respectively.

Aminopurvalanol A (5 and 40 μM; 8 hours) inhibits cell growth primarily by arresting the cells in the G2 phase of the cell cycle and, at higher concentration, triggering apoptosis.:Cell Cycle Analysis Cell Line:Human U937 leukemic cells Concentration:5 and 40 μM Incubation Time:8 hours Result:Increased the number of cells with a 4N DNA content as early as 8 h after the beginning of treatment at 5 μM. 40 μM led to cellular fragmentation and cells with an irregular DNA distribution, characteristic of apoptotic cell populations.Apoptosis Analysis Cell Line:Human U937 leukemic cells Concentration:5 and 40 μM Incubation Time:8 hours Result:40 μM Aminopurvalanol A led to apoptosis rather than after the beginning of treatment at 5 μM.

——

——

Angiogenesis

CDK

Gap Junction Protein|FTO

——

——

220792-57-4

403.91

C19H26ClN7O

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (247.58 mM)

CC(C)[C@H](CO)Nc(nc1Nc2cc(N)cc(Cl)c2)nc2c1ncn2C(C)C

——

(-20℃)

With Ice Pack

≥ 2 years